Skip to Content

News Releases

Sep 13 2021
SomaLogic Announces Analyst and Investor Meeting on September 28
NEW YORK and BOULDER, Colo., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual Analyst and Investor Meeting on Tuesday, September 28, 2021 from 11:00 a.m. to approximately 1:00 p.m. Eastern Time.
Sep 13 2021
SomaLogic announces strategic collaboration with UPMC to tailor clinical care through proteomics technology
BOULDER, Colo., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with leading health system UPMC to explore how the large-scale study of proteins and their functions in the body can effectively be
Sep 08 2021
SomaLogic Reports First Half of 2021 Financial Results
NEW YORK and BOULDER, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the six months ended June 30, 2021. “Our strong first half performance reflects our team’s dedication and execution across key
Sep 07 2021
SomaLogic to Present at Morgan Stanley 19th Annual Global Healthcare Conference
NEW YORK and BOULDER, Colo., Sept. 07, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference.
Sep 01 2021
SomaLogic Closes Business Combination and Will Begin Trading Under the Ticker “SLGC” on the Nasdaq Stock Exchange
SomaLogic to debut on Nasdaq as a leading publicly traded AI-data driven proteomics platform company Business combination results in approximately $630 million in gross cash proceeds to catalyze organic and inorganic growth initiatives Combined company to trade on Nasdaq under ticker “SLGC” NEW
Aug 31 2021
SomaLogic expands leadership team with new positions to drive commercial success
NEW YORK and BOULDER, Colo., Aug. 31, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, a leader in AI data-driven proteomics technology, today announced the recent appointments of Todd Johnson as Executive Vice President of Business Development and Strategy and Ruben
Aug 23 2021
SomaLogic Provides 2021 Financial Guidance Exceeding Initial Merger Combination Projections
NEW YORK and BOULDER, Colo., Aug. 23, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc. (“SomaLogic” or the “Company”), a leader in AI-data driven proteomics technology, today announced that with the approach of the business combination closing, the Company expects
Aug 18 2021
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of
Aug 16 2021
SomaLogic Announces Registration Statement Declared Effective and Reports 176% Y/Y Second Quarter and 187% First Half of 2021 Revenue Growth
NEW YORK & BOULDER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the registration statement for their business combination has been declared effective by the US Securities
Aug 12 2021
SomaLogic’s Melody Harris Honored with C-Suite Award by the Denver Business Journal
NEW YORK and BOULDER, Colo., Aug. 12, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, a leader in AI data-driven proteomics technology, today announced that Melody Harris, President and Chief Operating Officer has been named a 2021 C-Suite Award winner by the Denver
Displaying 1 - 10 of 23